Champions Oncology Stock (NASDAQ:CSBR)
Previous Close
$6.42
52W Range
$5.50 - $9.63
50D Avg
$5.95
200D Avg
$6.39
Market Cap
$90.26M
Avg Vol (3M)
$9.13K
Beta
0.40
Div Yield
-
CSBR Company Profile
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
CSBR Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Apr 25 | Apr 24 | Apr 23 |
|---|---|---|---|
| Product and Service, Other | $3.68M | $3.10M | - |
| License and Maintenance | $4.68M | - | - |
| Pharmacology Services | $48.59M | $47.03M | $50.71M |
| Personalized Oncology Services | - | $18.00K | $116.00K |
| Other Services | - | - | $3.05M |
Fiscal year ends in Apr 25 | Currency in USD